MannKind, Thirona Bio Extending Joint Work on Inhalable PF Therapy

MannKind, Thirona Bio Extending Joint Work on Inhalable PF Therapy

315700

MannKind, Thirona Bio Extending Joint Work on Inhalable PF Therapy

MannKind Corporation has extended its collaboration with Thirona Bio to continue work toward an inhaled therapy for fibrotic diseases affecting the lungs, including idiopathic pulmonary fibrosis (IPF). Under a collaboration established last year, the companies are evaluating the therapeutic potential of FBM5712, an investigational medicine designed to block the action of the pro-fibrotic signaling protein TGF-beta. This protein triggers the production and buildup of proteins like collagen that surround and support cells, leading to tissue scarring…

You must be logged in to read/download the full post.